Study NR1-02

Phase 1/2a Safety and Activity Dose-Escalation Study

The Phase 1/2a study, entitled “A Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects with Chronic Ischemic Subcortical Stroke (ISS),” evaluated the safety and preliminary efficacy of CC-101 in subjects with chronic ischemic stroke and stable motor deficits.

Study details

Window of Eligibility

6 months to 5 years post-stroke

Subjects

18 subjects

Primary Endpoint

Safety and tolerability

Status

Completed, with subject transition to long-term follow-up

CC-101 Doses Studied

2.5, 5.0, 10.0, and 20.0 million cells

Key Results

100% of subjects experienced some degree of motor function improvement
No reported serious or severe adverse events within 12 months of CC-101 treatment

All trials Contact clinical team

Information on this page is provided for educational purposes. Clarion Cells does not provide medical advice. Please consult your physician for treatment decisions. Clinical trial participation is subject to eligibility criteria.

Loading…